MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Assertio Holdings Inc

Закрыт

0.67

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.65

Макс.

0.67

Ключевые показатели

By Trading Economics

Доход

-7.6M

-10M

Продажи

3M

32M

Прибыль на акцию

-0.03

Рентабельность продаж

-32.552

Сотрудники

58

EBITDA

-8M

-3.4M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+325.37% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

5 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-15M

66M

Предыдущая цена открытия

0.67

Предыдущая цена закрытия

0.67

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Assertio Holdings Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 апр. 2025 г., 23:04 UTC

Главные новости

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 апр. 2025 г., 22:40 UTC

Главные движущие силы рынка

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 апр. 2025 г., 22:18 UTC

Приобретения, слияния, поглощения

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 апр. 2025 г., 18:51 UTC

Приобретения, слияния, поглощения

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 апр. 2025 г., 23:43 UTC

Обсуждения рынка

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 апр. 2025 г., 23:41 UTC

Обсуждения рынка

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 апр. 2025 г., 22:22 UTC

Приобретения, слияния, поглощения

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 апр. 2025 г., 22:21 UTC

Приобретения, слияния, поглощения

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 апр. 2025 г., 21:43 UTC

Главные новости
Отчет

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

3 апр. 2025 г., 20:43 UTC

Обсуждения рынка

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 апр. 2025 г., 20:34 UTC

Главные новости

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 апр. 2025 г., 20:23 UTC

Главные новости

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 апр. 2025 г., 20:15 UTC

Приобретения, слияния, поглощения

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 апр. 2025 г., 19:55 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

3 апр. 2025 г., 19:55 UTC

Обсуждения рынка

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 апр. 2025 г., 19:21 UTC

Обсуждения рынка

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 апр. 2025 г., 19:15 UTC

Обсуждения рынка

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 апр. 2025 г., 18:45 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

3 апр. 2025 г., 18:45 UTC

Обсуждения рынка

Gold Drops In Tariff Fallout -- Market Talk

3 апр. 2025 г., 18:39 UTC

Обсуждения рынка

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 апр. 2025 г., 18:38 UTC

Главные новости

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 апр. 2025 г., 18:30 UTC

Главные новости

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 апр. 2025 г., 18:20 UTC

Обсуждения рынка

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 апр. 2025 г., 18:18 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

3 апр. 2025 г., 18:17 UTC

Обсуждения рынка

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 апр. 2025 г., 18:04 UTC

Обсуждения рынка

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 апр. 2025 г., 17:55 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Assertio Holdings Inc Прогноз

Целевая цена

By TipRanks

325.37% рост

Прогноз на 12 месяцев

Средняя 2.85 USD  325.37%

Максимум 3.5 USD

Минимум 1.75 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Assertio Holdings Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

4

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

0.6558 / 0.7099Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Assertio Holdings Inc

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.